

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61N 1/05	A1	(11) International Publication Number: WO 91/19533 (43) International Publication Date: 26 December 1991 (26.12.91)
(21) International Application Number: PCT/US91/04122 (22) International Filing Date: 11 June 1991 (11.06.91) (30) Priority data: 539,102 15 June 1990 (15.06.90) US (71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue N.E., Minneapolis, MN 55432 (US). (72) Inventors: STOKES, Kenneth, B. ; 7657 Unity Avenue N., Minneapolis, MN 55432 (US). LINDEMANS, Fred ; Grootveldstaat 14, NL-6141 LT Limbricht (NL). (74) Agents: RISSMAN, John, A. et al.; Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MINIATURE STEROID ELUTING PACING LEAD ELECTRODE (57) Abstract A small diameter, unipolar or bipolar, atrial or ventricular transvenous or epimyocardial pacing lead with a porous, platinumized, steroid eluting cathode electrode exhibiting an effective surface area in the range of 0.1 to 4.0 mm ² , preferably 0.6 to 3.0 mm ² , provides low stimulation thresholds in the range of 0.5 volts, 0.5 milliseconds, very high pacing impedance (800 to 2,000 Ω), relatively low polarization, good to excellent sensing, and adequately low source impedance. The high pacing impedance prolongs the longevity of pacing pulse generators and allows for the miniaturization of their components. The low thresholds allow large safety factors at low applied voltages, which also contribute to increased battery longevity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

MINIATURE STEROID ELUTING PACING LEAD ELECTRODE.

BACKGROUND OF THE INVENTIONField of the Invention

5 This invention relates generally to chronically implanted medical electrode leads and, in particular, to cardiac pacing leads with an electrode structure which minimizes chronic pacing thresholds and drain on the pacing pulse generator power source.

10 Description of the Prior Art

 The safety, efficacy and longevity of an implanted pacemaker system depends (in part) on the performance of its pacing lead(s), the electronic circuits of the pacemaker pulse generator, the integrity of the pulse generator and
15 the capacity and reliability of the pulse generator power source. These inter-related components of the pacemaker system optimally are matched in a fashion that accommodates ever increasing demands on the modes of operation and function of the system in conjunction with an overall
20 reduction in its size, an increase in its longevity and an increased expectation in the reliability of the entire system. During the past thirty years, the technology of cardiac pacing has significantly advanced, with implantable pacemakers displaying an ever increasing variety of pacing
25 modalities, substantially broadening the indications for pacemaker use. In conjunction with this advancement, there has been extensive research and development effort expended to optimize the performance of pacing leads and their reliability.

30 In the past ten years, substantial improvements in reliable stable chronic pacemaker stimulation and sensing thresholds have been achieved which in turn have allowed the

-2-

development of smaller and longer-lived pacemakers that can be used with those leads with excellent safety margins and reliability. As new circuits are developed with lower "overhead" current drains, however, and as the circuits increase in complexity to allow for ever increasing pacemaker capabilities in their programmable functions, modes and memory, the longevity of the device depends increasingly more on the characteristics of the lead. In addition, implanters prefer that pacing lead bodies be made ever thinner, to occupy less space in the venous system, without diminishing or detracting from the mechanical strength and integrity of the lead body.

In the early days of cardiac pacing, very high geometric surface area electrodes were employed with bulky and short-lived pacemaker pulse generators. Early investigators including Dr. Victor Parsonnet advanced designs of pacing electrodes for achievement of low polarization and low thresholds while presenting a relatively small effective surface area for the delivery of a stimulating impulse in designs known as differential current density (DCD) of the type shown in U.S. Patent No. 3,476,116. The DCD electrode (like all pacing electrodes of that time) suffered excessive chronic tissue inflammation and instability and was not pursued commercially.

Subsequent researchers, including Dr. Werner Irnich explored in considerable detail the electrode-tissue interface and sought to arrive at an optimum exposed electrode surface area for both stimulation thresholds and sensing. Dr. Irnich in "Considerations in Electrode Design For Permanent Pacing" published in Cardiac Pacing; Proceedings of the Fourth International Symposium of Cardiac Pacing (H.J. Thalen, Ed.) 1973, pages 268-274, argued that the field strength (E) required to stimulate varies as $E =$

-3-

$\frac{v}{r} [1/r + d]^2$ where v equals applied voltage (threshold, v), r equals electrode radius and d equals fibrous capsule thickness. He further argues that the mean value for d equals about 0.7 mm, regardless of electrode radius. Therefore, the smaller the electrode radius the lower threshold (assuming E is a constant) until r equals d . When $r < d$, thresholds rise again. Dr. Irnich had concluded that the exposed hemispherical electrode at the tip of the lead should have a radius in the order of 0.7 to 1.0 mm which would result in an exposed surface area of 3 - 6 mm². However, Dr. Irnich went on in his article to propose a somewhat different design employing wire hooks designed to penetrate the myocardium to hold the electrode in position. These active fixation wire hook electrodes never achieved popularity and were supplanted by passive fixation tined and active fixation screw-in endocardial pacing leads.

In a later paper, "Acute Voltage, Charge and Energy Thresholds as Functions of Electrode Size for Electrical Stimulation of the Canine Heart", by F.W. Lindemans and A.N.E. Zimmerman; Cardiovascular Research, Vol. XIII, No. 7, pp. 383-391, July, 1979, the author demonstrates that an electrode radius of about 0.5 mm is optimal in the acute situation. However, it was recognized that the benefits of a small electrode surface area would be lost when the fibrous capsule gets thicker than about 0.5 mm (as Irnich also states), and for that reason (and others stated in the article), electrodes of such small surface area could not be used chronically.

Dr. Seymour Furman had also studied the relationship of electrode size and efficiency of cardiac stimulation and presented a ball-tip/exposed spaced coil electrode and a small hemispheric electrode in his article entitled "Decreasing Electrode Size and Increasing Efficiency of

-4-

Cardiac Stimulation" in Journal of Surgical Research, Volume 11 Number 3, March, 1971, pages 105-110. Dr. Furman concluded that the practical lower limit of electrode surface area was in the range of 8 mm² observing that impedance increased as an inverse function of the surface area.

Electrodes of many shapes including cylindrical, ball-tip, corkscrew, ring tip and open cage or "bird cage" configurations were pursued with exposed electrode surface areas tending toward 8 mm² in the mid 1970's.

More recently, various investigators have emphasized materials and their relationship to the considerations involved in optimizing electrode design. For example, the Medtronic U.S. Patent No. 4,502,492 discloses a low polarization, low threshold electrode design of the early to mid 1980's which was commercialized as the "Target Tip®" pacing leads in numerous models including Models 4011, 4012, 4511 and 4512. The tip electrode of the Target Tip® leads was generally hemispherical and provided with circular grooves. The electrode was fabricated of platinum, coated over its external surface with a plating of platinum black. The combination of the relatively low electrode surface area and platinum black contributed to state-of-the-art thresholds in that time period. Other manufacturers marketed porous platinum mesh (Cardiac Pacemakers, Inc.), totally porous sintered (Cordis Corporation), glassy and vitreous carbons (Siemens), and laser drilled metal (Teletronics Ppty. Ltd.) electrodes in that same time period.

A considerable breakthrough in the development of low threshold electrode technology occurred with the invention of the steroid eluting porous pacing electrode of Stokes U.S. Patent No. 4,506,680 and related Medtronic U.S. Patent Nos. 4,577,642, 4,606,118 and 4,711,281, all incorporated

-5-

herein by reference. The electrode disclosed in the '680 patent was constructed of porous, sintered platinum or titanium, although carbon and ceramic compositions were mentioned. Within the electrode, a plug of silicone rubber
5 impregnated with the sodium salt of dexamethasone phosphate or the water soluble forms of other glucocorticosteroids was placed in a chamber. The silicone rubber plug allowed the release of the steroid through the interstitial gaps in the porous sintered metal electrode to reach the electrode-
10 tissue interface and prevent or reduce inflammation, irritability and subsequent excess fibrosis of the tissue adjacent to the electrode itself. The porous steroid eluting electrodes presented a source impedance substantially lower compared to similarly sized solid
15 electrodes and presented significantly lower peak and chronic pacing thresholds than similarly sized solid or porous electrodes. Those two advantages of steroid eluting electrodes allowed the use of relatively small surface area electrodes of about 5.5 mm² (CAPSURE® SP Model 5023, 5523
20 leads sold by Medtronic, Inc.) to raise the pacing impedance without sacrificing the ability to sense heart activity. The smaller electrode size permitted by the '680 patent invention resulted in higher current density during stimulation pulses, provided more efficient stimulation of
25 the heart tissue with lower current drain from the implanted pacemaker power source. In addition, the localized nature of the drug treatment minimized the systemic assimilation of the drug and avoided undesirable side effects for the patient.

30 The 8 mm² surface area CAPSURE® steroid eluting lead Models 4003, 4503, 4004, and 4504 sold by Medtronic, Inc. have enjoyed remarkable commercial success to the present time. However, many physicians are not taking full advantage of properties of the electrode to save battery

-6-

current and, therefore, longevity attainable by programming pacemaker pulse voltage to a safety margin level above the thresholds afforded by these leads. The quest to provide even lower stimulation thresholds and improved sensing and
5 otherwise increase the performance and reliability of the pacing leads continues. One objective is to achieve markedly lower stimulation thresholds and to convince the physicians to accept and program lower voltage stimulation pacing pulses.

10 The impedance of the lead as a whole is a function of the resistance of the lead conductor and the electrode tip as well as the effective impedance of the electrode-tissue interface. An inefficient way or means to raise impedance is to increase the resistance of the conductors. This
15 wastes current as heat. It is preferable to decrease lead current drain with more efficient control of the electrode-tissue interface impedance. This can be done by reducing the geometric surface area of the cathode. However, it is commonly believed that small electrodes are inefficient at
20 sensing natural depolarizations of the cardiac tissue. This is not necessarily true, however. The amplitude of the intrinsic cardiac depolarization signals (typically the ventricular QRS and/or atrial P-wave complexes) is essentially independent of electrode size, as measured on a
25 high, megohm range input impedance oscilloscope. The problem is that the sense amplifiers of modern pulse generators have comparatively lower input impedance - typically about 35k Ω . The impedance of the QRS or P-wave signal (or "source impedance") increases as the electrode
30 surface area decreases. Thus, a 5 mm² polished electrode will produce QRS or P-waves with about 5k Ω source impedance. According to Kirchof's law, the attenuation of the signal in the generator's amplifier is $1/(1 + Z_{in}/Z_s)$ where Z_{in} is the input impedance of the amplifier and Z_s is the source

-7-

impedance of the signal to be sensed. Thus, a 5k Ω signal into a 35k Ω amplifier will have its amplitude reduced by $1/(1 + 35/5) = 12.5\%$. In marginal cases, this may make the difference between being able to sense properly or not being able to sense. Therefore, it is important to keep the source impedance low, preferable to attenuate less than 5% of the cardiac signal, that is, $Z_s < 1800\Omega$, for a 35 k Ω amplifier.

Thus, there is a trade-off with geometric surface area of the cathode electrode between the demands for low current drain and adequate sensing. In addition, it is desirable to achieve relatively low polarization effects so that they do not distort the electrogram of evoked or intrinsic cardiac depolarizations or leave a postpulse potential of sufficient magnitude to be mistakenly sensed as a QRS or P-wave by the amplifier.

SUMMARY OF THE INVENTION

It is thus an object of the present invention to reduce the effective surface area of pacing electrodes to a point well below the presently accepted dimensions to increase pacing impedance without increasing thresholds and without negatively impacting sensing capabilities.

The present invention provides a body-implantable lead for the delivery of an electric stimulus to a desired body site, particularly the atrial or ventricular chambers of a patient's heart. This lead presents a very high (greater or equal to 800 ohm) pacing impedance with low peak and chronic thresholds, low source impedance and excellent sensing in a size of approximately 1.5 mm² exposed geometric (or macroscopic) surface area. Specifically, the lead of the present invention possesses an electrode with an exposed geometric surface area in the range of 0.1 - 4.0 mm²,

-8-

preferably between 0.6 and 3.0 mm², with about 1.0 mm² providing optimum performance. The lead has a pacing impedance of 1400 ± 260 ohms, a source impedance of about 1650 ± 410 ohms in both chambers of the heart. The lead of 5 the present invention constitutes a pacing lead having a spherical, hemispheric or disk shaped exposed distal tip electrode of approximately 1 millimeter in diameter fabricated of platinized porous platinum (or other porous electrode material), loaded with glucocorticosteroid. In at 10 least one embodiment, the electrode is attached to the distal end of a pacing lead of about 1.0 mm or 3 to 4 French in overall diameter.

Both endocardial and epicardial leads may be fabricated in accordance with the teachings of the present invention.

15 In another aspect of the present invention, DCD electrode technology may be successfully employed with a steroid eluting release device and with apertures in the range of 0.1 to 4.0 mm².

BRIEF DESCRIPTION OF THE DRAWINGS

20 These and other objects and advantages of the present invention may be fully understood and appreciated in conjunction with the attached drawings and the following detailed description of the preferred embodiments where the same numerals are employed to denote the same or similar 25 features throughout:

Figure 1 shows a side plan view of an endocardial, unipolar, ball-tip electrode pacing lead according to the present invention;

Figure 2 shows a cross-sectional view of the ball-tip 30 electrode of the lead shown in Figure 1;

Figure 3 shows an end plan view of the distal tip of the electrode of the lead shown in Figure 1;

-9-

Figure 4 shows a cross-sectional view of the distal portion of an endocardial, unipolar, DCD electrode pacing lead, according to the present invention;

Figure 5 shows an end plan view of the distal tip of
5 the DCD electrode of the lead shown in Figure 4;

Figure 6 shows a cross-sectional view of the distal tip portion of a further endocardial, bipolar, cylindrical tip electrode pacing lead according to the present invention;

Figure 7 shows an end plan view of the distal tip
10 electrode of the lead shown in Figure 6;

Figure 8 shows a cross-sectional view of the distal tip portion of a further embodiment of the ball-tip electrode according to the present invention;

Figure 9 shows a cross-sectional view of the distal
15 electrode of a modified DCD electrode according to the present invention;

Figure 10 shows a plan view of the distal portion of a bipolar epicardial pacing lead according to the present invention;

20 Figure 11 shows a cross-sectional view of the distal tip portion of the electrode, preferably employed in the epicardial electrode of Figure 10;

Figure 12 depicts graphically the performance of the exposed electrodes of the present invention with steroid
25 elution against electrodes of the same size and configuration without steroid elution; and,

Figure 13 depicts graphically the performance of a DCD electrode of the present invention with steroid elution against a test DCD electrode of the same size and
30 configuration without steroid elution.

-10-

DETAILED DESCRIPTION OF THE DRAWINGS

Before describing the specific features of the preferred embodiments of the present invention certain matters should be defined. First of all, the practice of the present invention contemplates the employment of a steroid or other drug with an electrode possessing a mechanism for allowing the drug to be eluted through and/or around the electrode in order to reach the endocardial or myocardial cells in the vicinity of the tip of the pacing lead in order to reduce, if not eliminate entirely, the acute and chronic inflammation occasioned by the cellular foreign body and physical irritation response to the tip of the lead. As described in the aforementioned Stokes' patents, the electrode is preferably fabricated of body compatible electrically conducting material with or without specific steroid eluting passages but generally with a porous structure either throughout the body of the electrode or at its surface. The porosity of the electrode surface or body provides a large surface area for sensing whereas the overall dimension or shape of the exposed electrode defines a comparatively smaller surface area for stimulation. The porous structure thus presents a microscopic (or "fractal") large surface area for sensing and a macroscopic or geometrically measured very small surface area for stimulation. Acceptable electrode materials and the associated fabrication techniques employed to achieve the micro-porous structure, as well as the porosity of that structure are all set forth in the aforementioned prior art patents and in the Richter et al U.S. Patent No. 4,773, 433, the Heil et al U.S. Patent No. 4,819, 661, the Thoren et al U.S. Patent No. 4,149,542, the Robblee U.S. Patent No. 4,677,989, the Heil et al U.S. Patent 4,819,662, the Mund et

-11-

al U.S. Patent No. 4,603,704, the Skalsky et al U.S. Patent No. 4,784,161, and the Szilagyi U.S. Patent No. 4,784,160 and other patents and literature in the prior art.

Furthermore, the present invention may be practiced in the context of electrode structures that have heretofore been referred to as conventional exposed electrodes and the DCD electrode structures of the type shown in the aforementioned Parsonnet patent. In this regard, it will be observed in the following description of the preferred embodiments that electrodes of the present invention may be fabricating having characteristics of both the conventional and the DCD electrode structures. Dr. Parsonnet, in his early work on the DCD electrode, sought to reduce the polarization overvoltage (shown in Figure 2 of his '116 patent) and the resulting postpulse polarization voltages which made and still make it difficult to distinguish the heart's P-waves or R-waves from those postpulse polarization voltages within 5 to 100 milliseconds after the delivery of the stimulus. In the practice of the present invention, the electrodes may be internalized in the DCD manner or externalized in the conventional manner. In the DCD context, the macroscopic surface area through which current is emitted during stimulation is defined by the aperture area presented to the cells in the vicinity of the tip of the pacing lead. The large, microscopic surface area is effected, as shown in Figure 4 of the Parsonnet '116 patent, by the conductor coil within the distal portion of the lead body. In the present invention, the conductor coil may be rendered textured or porous by one or more of the aforementioned techniques, and steroid is eluted as described further herein below. Figure 1 illustrates a plan view of an exposed electrode constructed in accordance with the present invention. The lead includes an elongated lead body 10 covered by an insulative sleeve 12. Insulative

-12-

sleeve 12 may be fabricated of any flexible biocompatible and biostable insulator especially silicone rubber or polyurethane. At the proximal end of the lead, terminal assembly 14 is adapted to couple the lead to an implantable
5 pacemaker pulse generator. Terminal assembly 14 is provided with sealing rings 16 and a terminal pin 18, all of a type known in the art. An anchoring sleeve 20 (shown partially in cross-section) slides over lead body 10 and serves as a point for suturing the lead body to body tissue at the
10 insertion point of the lead into the vein or tissue in a fashion known in the art. Anchoring sleeve 20 and terminal assembly 14 may be conveniently fabricated of silicone rubber.

The lead shown in Figure 1 further includes a stylet
15 guide 11 and stylet assembly 13 coupled to the terminal pin 18 for imparting stiffness to the lead during the insertion and placement of the lead transvenously into either the right ventricle or the right atrium of the heart. The stylet guide and stylet assembly are discarded after use and
20 before connection of the terminal pin 18 to a pacemaker pulse generator.

At the distal end of the lead 10, a tine protector 15 is shown (in cross-section) protecting the tines until the lead is used. Tines 26 are employed to passively retain the
25 tip electrode 22 in position against the endocardium as is well known in the pacing art.

The lead assembly 10 of Figure 1 includes a multifiler conductor coil extending from the terminal pin 18 to the tip electrode 22. Figure 1 depicts a unipolar lead and it
30 should be understood that the present invention may be implemented in a bipolar lead design employing a second conductor extending from a second exposed cylindrical terminal surface area near the proximal end of the lead to an exposed ring electrode spaced ≥ 8 mm from the distal tip

-13-

electrode 22 as is well known in the art. The ≥ 8 mm spacing is necessary because the current sense amplifier bandpass center frequency is about 25-30 Hz. Closer spacings are possible if the sense amplifier bandpass center frequency is shifted to higher values accordingly, and if higher gains are used.

Referring now to Figure 2, it shows in cross section a view of the distal lead portion of the preferred embodiment of the electrode of the present invention and its connection to the lead conductor 28. In Figure 2, the distal electrode 22 is depicted as a porous platinum ball covered with platinum black at the end of a metal pin 23 of platinum extending from the tip electrode 22 to the distal end of the conductor coil 28. The conductor coil 28 is attached to the proximal end of the pin by crimping at point 34 of crimping member 36 at the time of manufacture. Silicone adhesive may be used at point 32 to seal the assembly against leakage of blood into the conductor coil. The insulative sheath 12 is shown placed over the crimping member as well as the tine assembly 38 which is fit between the distal end of the insulative sheath 12 and the crimping member 54. A steroid-silicone rubber compound ring 40 is located proximal from the electrode ball.

Referring now to Figure 3, the end view of the ball-tip electrode 22, tines 26 and tine assembly 38 is shown. The ball-tip distal electrode 22 is constructed as shown in Figures 2 and 3 to present a circular, hemispheric or spherical exposed macroscopic surface area in the range between 0.1 and 4.0 square mm². The ball-tip electrode 22 is fabricated of porous, sintered platinum having a porosity in the range of .5 to 100 microns, employing "splat" powder in the sintering process.

The porous platinum electrode is electroplated with platinum black and the porosity, together with the platinum

-14-

black coating is intended to reduce source impedance and polarization. The silicone backing sleeve 40 forms a monolithic controlled release device (MCRD), as it is loaded with an anti-inflammatory agent, e.g., a steroid

5 dexamethasone sodium phosphate. The steroid also is deposited within the pores of the porous platinum electrode 22 by application of a solution of 200 mg U.S.P. dexamethasone sodium phosphate dissolved in 5.0 cc isopropanol and 5.0 cc distilled or deionized water as

10 described in the aforementioned Stokes' patents. The MCRD weight and composition as well as the electrode surface area are critical to the electrode's overall performance. The small geometric macroscopic electrode size is intended to produce very high pacing impedance. The porous surface

15 configuration together with platinum black electroplating and steroid contribute to a microscopically large surface area for low polarization, low source impedance and low thresholds. The porous surface also facilitates the retention of steroid and adhesion of the platinum black to

20 the electrode surface. Referring now to Figures 4 and 5, they depict a DCD electrode fabricated in accordance with the teachings of the present invention. A platinized coil 50 of platinum wire is crimped to conductor coil 28 using crimp sleeve 52 and crimp core 58. Silicone rubber adhesive

25 54 may be used to provide a seal to assure that blood does not leak into the conductor coil. The polymeric insulation tubing 12 extends to the end or just beyond the end of platinized coil 50. Three or four symmetrically placed tines 26 are placed close to the distal orifice or aperture

30 56. The aperture 56 of the tubing 12 presents a circular hole of 0.1 to 4.0 mm², about 0.62 mm² as shown. The lumen of the platinized coil is filled with a solution of 200 mg dexamethasone sodium phosphate in 5 cc water and 5 cc isopropanol. The solvents are allowed to evaporate, leaving

-15-

a coating of steroid on the coils. The steroid loaded MCRD 40 is located at the proximal end of the platinized coil. The exposed surface of the platinized coil 50 must be large enough, preferably $\geq 50 \text{ mm}^2$, to produce low polarization.

5 Past DCD electrodes required that the distal lumen be filled with conductive saline prior to insertion into the vein. This is not required with the steroid loaded lead, because the steroid acts as a wetting agent, allowing blood to fill the lumen as the lead is pushed down the vein.

10 In operation, charge transfer from electronic to ionic conduction occurs at the interface of the platinized coil and the blood or fibrotic tissue that eventually fills the lumen. Because this surface is large, polarization losses are low. Electric current is conducted through the blood
15 and fibrotic tissue to the heart muscle to provide stimulation. Because the aperture 56 is small, acute thresholds are low and pacing impedance is high. The steroid controls inflammation in the surrounding tissue and helps to prevent or reduce chronic threshold rise.

20 Referring now to Figures 6 and 7, they depict an alternative design of the bipolar, endocardial pacing lead of the present invention, and in particular, a modified electrode assembly of the present invention. The lead of Figure 6 is constructed in similar fashion to the lead of
25 Figures 1-3 and, to the extent possible, the same numerals will be employed to describe the same or equivalent elements of these two embodiments of the lead. The principal differences between Figures 1-3 and Figures 6 and 7 are that the lead of Figures 6 and 7 is bipolar, possessing a ring
30 electrode 60 spaced from tip electrode 22', the tine elements 26 are constructed somewhat differently and the quadrafilier conductor coil 28 comprises two pair of bifiler, commonly wound, separately insulated conductors, each respectively connected to one of the two electrodes. Thus,

-16-

at point 62, two of the conductor wires are attached to the ring electrode 60, and at point 64 the remaining two conductor wires contact the pin 23 and crimp sleeve 36 which is crimped against the coils 64 at point 34. The pin 23 extends through the steroid impregnated ring 40.

The tip electrode 22' is fabricated of the same materials and treated in the same fashion as the tip electrode 22 of the embodiment of Figures 1-3. Figures 6 and 7 thus illustrate a bipolar embodiment of the pacing lead of the present invention.

Turning now to Figure 8, it discloses a further ball-tip electrode 22'' attached to a pin 23 extending back to a similar connection with a coiled wire conductor (not illustrated). The tip electrode 22'' is virtually fully exposed as is a portion of the distal end of the steroid eluting MCRD 40'. Thus the electrode depicted in Figure 8 illustrates an extreme example of the exposed "nanotip" concept of the present invention and may be employed in either endocardial or epi/myocardial lead designs where the tip electrode may penetrate myocardial tissue. The exposed surface of the MCRD 40' thus allows for steroid elution in a path in both through and around the spherically shaped electrode 22 ''.

Turning now to Figure 9, it depicts a still further embodiment of the distal portion of the electrode of the present invention. The electrode of Figure 9 is a modification of the electrode depicted in Figures 1 to 3 except that, unlike the electrode depicted in Figure 8, the ball-tip electrode 22''' is fully retracted within the distal portion of the tine bearing member 38. The inside diameter of the lead tip, that is the inside diameter of the tine element 38, is preferably .040 inches which equals a 0.8 mm² orifice. Only a hemispheric portion of the surface

-17-

of the ball electrode 22''' is exposed in this embodiment of the invention.

The aforementioned embodiments of the present invention are all illustrated as endocardial pacing leads wherein the electrode or lead tip may or may not be designed to pass through the endocardium and into the myocardium of the heart. In substitution for the tined fixation mechanisms shown, any of the endocardial lead embodiments may be provided with active screw-in fixation mechanisms.

10 Figures 10 and 11 depict a further embodiment wherein the concept of the present invention is embodied in a bipolar epicardial pacing lead wherein the tip electrode 22'''' is mounted on a stem 70 extending from a platform 72 of an epicardial lead body 74 to penetrate into the
15 myocardium. While not specifically shown, the epicardial lead of Figure 10 may be affixed in place by fixation hooks or screws (partially shown at 78) or sutures. The specific configuration of the electrode 22'''' may take the form of any of the electrodes 22 - 22''' previously described with
20 the exception that the outer surface or tubular member of the extension 70 may need to be stiff enough to allow the tip electrode to penetrate the epicardial membrane. It will be understood, furthermore, that the epicardial version of the lead of the present invention may further incorporate a
25 DCD design within body 74 or 70 of the type shown, for example, in the aforementioned Parsonnet '116 patent.

However, preferably the tip electrode 22'''' and stem 70 are constructed as shown in Figure 11. The stem 70 preferably comprises a hollow metal tube 80 having an MCRD
30 40 located at any point therein between the tip electrode 22'''' and the point where the tube is mechanically and electrically connected to the conductor coil (not shown) within housing 74. The tip electrode 22'''' is attached to the tip of tube 80, and the exterior of the tube 80 is

-18-

insulated by outer tube 12. The steroid in the MCRD 40 elutes through the porous tip electrode 22''''.

The bipolar mesh electrode 76 shown in Figure 10 may also be soaked with steroid in same fashion as tip electrode 5 22'''''. The epicardial lead may also be constructed in unipolar fashion substituting a porous fabric for metallic mesh electrode 76 to allow fixation to the epicardium by fibrotic tissue ingrowth. Said unipolar leads may also be fixed to the heart by sutures, obviating the need for the 10 fabric mesh. Such leads may otherwise possess the features of Medtronic U.S. Patent No. 4,010,758 and designs discussed in a paper by K. Stokes, "Preliminary Studies on a New Steroid Eluting Epicardial Electrode", PACE, Vol. 11., pp. 1797 - 1803, November, 1988, incorporated herein by 15 reference.

The electrodes of each of the foregoing embodiments may be fabricated by coating machined electrode blanks or by dipping the end of pin 23 (of Figures 1-3 and 6-10) into a binder, then dipping it into a fluidized bed of platinum 20 splat powder, which adheres to the pin 23 in a generally ball shape, and then sintering the powder. The electrode of Figure 11 may be constructed by applying a mixture of the binder and splat powder to the opening of the tube 80 and then sintering it in situ.

25 The previously described embodiments of the present invention are illustrative of the construction and features of the very small diameter tip electrodes and pacing leads of the present invention. As previously indicated, the prior art had progressed to the point where the lower limit 30 for effective macroscopic surface areas was believed to be within the range between 5.5 mm² and 8 mm². Studies that we have conducted with steroid free, small macroscopic surface area porous electrodes in both the exposed and DCD

-19-

configuration confirmed the expectation and findings of the aforementioned prior investigators in the field.

In regard to exposed electrodes of the present invention with steroid compared to those electrodes without steroid, the difference in stimulation thresholds is striking. Figure 12 depicts the results of a paired study in canines of the ventricular "nanotip" leads with and without steroid over an 8 week study period. The stimulation thresholds show a marked rise for the leads without steroid as compared to those leads with steroid.

-20-

The actual data from the paired "nanotip" ventricular canine study is set forth in Tables I and II as follows:

TABLE I

PAIRED VENTRICULAR DATA

5		Implant Time		0.5ms Threshold (v)		0.5 ms Pacing Impedance (Ω)	
	(Weeks)	N	No Steroid	With Steroid	No Steroid	With Steroid	
10	0	4	0.32 \pm .05	0.30 \pm .08	1300 \pm 200	1300 \pm 300	
	1	4	1.0 \pm .53	0.52 \pm .09	870 \pm 140	950 \pm 170	
	2	4	1.3 \pm .51	0.52 \pm .15	780 \pm 320	880 \pm 520	
	3	3	1.2 \pm .35	0.57 \pm .15	1000 \pm 210	1100 \pm 180	
	4	2	1.3 \pm .56	0.45 \pm .07	970 \pm 200	1160 \pm 330	
15	8	2	1.2 \pm .64	0.45 \pm .07	1200 \pm 430	990 \pm 48	

-21-

TABLE II

PAIRED VENTRICULAR DATA

Implant (Weeks)	N	R-Wave Amplitude (mV) (Slew Rate) (v/s)		R-Wave Source Imped. (Ω)		Time
		No Steroid	With Steroid	No Steroid	With Steroid	
5						
0	4	38 \pm 3.9 (\geq 8.4 \pm 1.9)	29 \pm 7.6 (\geq 6.7 \pm 4.2)	1400 \pm 330	1450 \pm 510	
10	1	4	26 \pm 4.9 (4.1 \pm 1.16)	29 \pm 5.7 (4.1 \pm 2.2)	1100 \pm 190	975 \pm 171
	2	3	25 \pm 5.7 (4.1 \pm 1.77)	27 \pm 2.2 (4.3 \pm 1.5)	1100 \pm 290	1200 \pm 270
	3	3	26 \pm 6.9 (4.2 \pm 1.38)	28 \pm 2.9 (5.0 \pm 1.8)	1000 \pm 200	1300 \pm 210
15	4	2	25 \pm 9.9 (4.1 \pm 1.85)	28 \pm 2.8 (5.7 \pm 0)	1150 \pm 210	1350 \pm 490
	8	2	27 \pm 4.2 (4.9 \pm 1.28)	31 \pm 1.4 (\geq 8.4 \pm 2.3)	1200 \pm 430	1000 \pm 0

20 In our studies without steroid, the DCD electrodes having apertures of 0.1 to 0.2 mm², and probably up to 0.5 mm² do not work. They go to exit block and stay there. A DCD electrode having a 0.6 mm² aperture without steroid exhibits a threshold rise of from 0.5 volts to over 8 volts

25 in three weeks as exhibited in the graph of Figure 13. However, with steroid, the same size DCD electrode exhibits a chronic threshold rise of from 0.5 volts to approximately 0.8 volts over a 12 week implant time as shown in the lower curve of Figure 13.

-22-

In regard to the performance of the DCD electrodes the data from the studies conducted in dogs are presented in the following Tables III and IV.

TABLE III

5 0.6 mm² APERTURE STEROID ELUTING DCD ELECTRODE AS A
FUNCTION OF IMPLANT TIME IN CANINES

(N = 5)

Implant Time	0.5ms Threshold	Pacing Impedance	R/P-Wave Amplitude	R/P- Wave Source Impedance	Slew Rate	
(Weeks)	(v)	(Ω)	(mV)	(s)	(v/s)	
VENTRICLE						
0	0.45 \pm .23	1300 \pm 570	29 \pm 5.9	2250 \pm 790	5.4 \pm 1.2	
15 1	0.85 \pm .50	1000 \pm 320	25 \pm 2.9	1400 \pm 500	4.0 \pm .83	2
	0.7 \pm .48	1000 \pm 670	28 \pm 1.9	1300 \pm 860	4.5 \pm 1/7	3
	0.67 \pm .38	1000 \pm 610	29 \pm 3.8	1300 \pm 740	4.4 \pm 1.8	4
	0.87 \pm .62	1300 \pm 617	28 \pm 3.9	1200 \pm 680	5.5 \pm 2.6	8*
	0.82 \pm .57	990 \pm 580	28 \pm 3.6	1100 \pm 670	4.4 \pm 2.7	
20 12*	0.82 \pm .57	1200 \pm 380	28 \pm 4.2	1300 \pm 420	4.6 \pm 2.7	

ATRIUM

0	.34 \pm .08	2900 \pm 220	13 \pm 3.6	3100 \pm 580	4.4 \pm 1.9	
	1.2 \pm .69	1400 \pm 210	6.2 \pm 2.0	1700 \pm 210	1.4 \pm 1.2	2
25 1.1 \pm .62	1600 \pm 190	7.6 \pm 2.4	2100 \pm 280	1.9 \pm 1.5		3
	0.7 \pm .33	1700 \pm 100	9.0 \pm 3.9	2200 \pm 420	2.2 \pm 1.5	4
	0.84 \pm .45	1700 \pm 110	8.2 \pm 2.7	1900 \pm 250	1.8 \pm 1.3	8
	0.28 \pm .08	1600 \pm 210	8.5 \pm 3.4	1800 \pm 270	2.6 \pm 1.8	12*
	0.47 \pm .09	1600 \pm 240	8.5 \pm 3.3	1700 \pm 0	2.5 \pm 1.9	
30	*N = 4					

-23-

TABLE IV

**PAIRED DCD THRESHOLDS AND
PACING IMPEDANCES**

Implant 5 Time			Exposed Electrode Area (mm ²)	0.5ms Thresholds(v)		Pacing Impedance(Ω)	
(Weeks)			N	No Steroid	With Steroid	No Steroid	With Steroid
10	0	1	0.15	0.8	2.1	19000	30000
	0	2	0.62	0.5	0.6	3300	4300
				±.3	±.07	±350	±2500
	1	0.15	6.9	>10	17000	39000	
	1	1	0.62	2.4	1.2	3400	4000
15	2	1	0.15	6.1	7.8	15000	26000
	2	1	0.62	5.0	1.4	3300	3500
	3	1	0.15	>10	3.8	----	38000
	3	1	0.62	6.5	2.2	3800	4400
	4	1	0.15	9.6	3.3	16000	33000
20	4	1	0.62	8.1	1.7	5400	3400

-24-

In regard to the myocardial electrodes of the type shown particularly in Figures 10 and 11, animal implant data of 1.5 mm² macroscopic surface area electrodes with and without steroid is presented in the following Tables V and 5 VI.

TABLE V

MYOCARDIAL 1.5 mm² ELECTRODES
CANINE VENTRICULAR STIMULATION

Implant 10 Time (Weeks)	0.5ms Thresholds		0.5ms Pacing Impedance(Ω)	
	With Steroid (N = 4)	No Steroid (N = 3)	With Steroid (N = 4)	No Steroid (N = 3)
0	0.50 \pm .10	0.35 \pm .10	4400 \pm 4500	3800 \pm 2100
15 1	0.86 \pm .40*	1.4 \pm .40	1400 \pm 350	1300 \pm 180
2	0.50 \pm .11	1.9 \pm .28	1600 \pm 210	1600 \pm 300
3	0.45 \pm .12	1.1 \pm .55	1600 \pm 150*	2150 \pm 1200
4	0.47 \pm .22	0.83 \pm .32	1600 \pm 210	1300 \pm 550
8	0.45 \pm .12	0.63 \pm .12	1400 \pm 160	1300 \pm 430
20 12	0.47 \pm .17	0.70 \pm .10	1200 \pm 270	1500 \pm 260**

* N = 3

-25-

** N = 2

TABLE VI

**MYOCARDIAL 1.5 mm² ELECTRODES
CANINE VENTRICULAR SENSING**

5	Implant Time	R-Wave			
		Amplitudes (mv)		Source Impedance (Ω)	
10	(Weeks)	With Steroid (N = 4)	No Steroid (N = 3)	With Steroid (N = 4)	No Steroid (N = 3)
	0	17 \pm 4.3	23 \pm 13	3900 \pm 1200	7600 \pm 1500
	1	17 \pm 5.7	19 \pm 1.0	2400 \pm 460	3400 \pm 510
	2	17 \pm 7.8	20 \pm 3.6	2500 \pm 450	3600 \pm 1500
	3	18 \pm 7.9	23 \pm 5.0	2600 \pm 330	2900 \pm 590
15	4	18 \pm 8.0	22 \pm 4.7	2400 \pm 220	3000 \pm 600
	8	24 \pm 7.1	23 \pm 5.3	1900 \pm 96	2300 \pm 610
	12	19 \pm 8.3	24 \pm 5.9	1800 \pm 220	2400 \pm 870

-26-

Thus it can be seen that the very small "nanotip",
exposed and DCD electrodes of the present invention satisfy
the aforementioned desirable characteristics of a pacing
lead, that has low stimulation thresholds very high pacing
5 impedance (800 - 2500 ohms) relatively low polarization,
good to excellent sensing, and adequately low source
impedance. The high pacing impedance prolongs the longevity
of pacing pulse generators and allows for the
miniaturization of their components. The low thresholds
10 allow large safety factors at low applied voltages, which
also contribute to increased battery longevity.

While the embodiments of the present invention have
been described in particular application to cardiac pacing,
it will be understood that the invention may be practiced in
15 other electrode technologies where the aforementioned
characteristics are desirable, including neurological and
muscle stimulation applications. Moreover, the
miniaturization of the electrodes afforded by the present
invention may advantageously allow the clustering of two or
20 more electrode structures at the tip of a
stimulation/sensing lead or probe. While not specifically
illustrated above, the present invention may advantageously
be implemented in tip electrode configurations of the type
illustrated in Sleutz et al U.S. Patent No. 4,662,382 in
25 order to provide practical closely spaced bipolar
stimulation and sensing.

The invention has been described in detail with
particular reference to the preferred embodiments thereof,
but it will be understood that variations and modifications
30 can be effected within the scope of the following claims.

-27-

What we claim is:

1. A body stimulation and sensing lead comprising:
an electrical conductor having a proximal end and
a distal end;
5 insulating sheath means for covering said
conductor between said proximal and distal end thereof;
electrical connector means coupled to said
proximal end of said conductor; and
electrode means electrically coupled to said
10 distal end of said electrical conductor for conducting
electrical energy to and from body tissue cells, said
electrode means having a macroscopic surface area of less
than 4.0 mm² exposed to body fluids and tissue; and wherein:
said electrode means comprises a porous metallic
15 or other conductive material with high microscopic surface
area in proportion to said macroscopic surface area over at
least a portion of said macroscopic surface area; and
said lead further comprises drug dispensing means
for dispensing a drug in the vicinity of said body tissue
20 cells.
2. A lead according to claim 1 wherein said drug is
the sodium salt of dexamethasone phosphate.
3. A lead according to claims 1 or 2 wherein said
drug dispensing means comprises a water permeable polymer
25 body located within said insulating sheath lead and adjacent
said electrode containing a water soluble form of said drug.
4. A lead according to claim 1 wherein said
macroscopic surface area of said electrode is in the range
of between 0.10 and 4.0 mm².

-28-

5. Lead according to claims 1 or 4 wherein the exposed surface of said electrode means is generally hemispherical in shape.

6. A lead according to claim 4 wherein said drug is the sodium salt of dexamethasone phosphate.

7. A lead according to claims 4 or 6 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

10 8. A lead according to claim 1 wherein said drug is an anti-inflammatory agent.

9. A lead according to claim 8 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said 15 electrode containing a water soluble form of said drug.

10. A lead according to claims 8 or 9 wherein said macroscopic surface area of said electrode is in the range of between 0.10 and 4.0 mm².

11. A lead according to claims 8 or 9 wherein said 20 macroscopic surface area of said electrode is in the range of between 0.60 and 3.0 mm².

12. A lead according to claim 1 wherein said electrode means is formed of porous metallic or other conductive materials from the class of materials consisting essentially 25 of platinum, palladium, titanium, tantalum, rhodium, iridium, carbon, vitreous carbon and alloys, oxides and nitrides of such metals or other conductive materials.

-29-

13. A lead according to claim 12 wherein said drug is an anti-inflammatory agent.
14. A lead according to claims 12 or 13 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.
15. A lead according to claims 12 or 13 wherein said exposed macroscopic surface area of said electrode is in the range of between 0.10 and 4.0 mm².
- 10 16. A lead according to claims 1 or 4 or 15 wherein said macroscopic surface area of said electrode is in the range of between 0.6 and 3.0 mm².
- 15 17. An implantable cardiac pacing lead comprising:
an elongated electrical conductor having a proximal and a distal end;
insulated sheath means covering said conductor between said proximal and distal ends;
electrical connector means coupled to said proximal end of said conductor for connecting said lead to a pulse generator;
20 electrode means electrically coupled to the distal end of said electrical conductor for conducting electrical energy to and from body tissue cells, said electrode means having a macroscopic surface area of less than 4.0 mm² exposed to body fluids and tissue;
25 means for electrically coupling the distal end of said conductor means to said electrode means at a point within said insulated sheath means;
drug dispensing means located at least
30 partially within said insulated sheath means at a position

-30-

proximal to said electrode means and said coupling means for dispensing a drug to said body tissue cells; and
means for providing a pathway for the application of said drug to said tissue cells.

5 18. A lead according to claim 17 wherein:

said electrode means is composed of a metallic or other conductive material and at least a portion of which is porous; and wherein:

10 said drug dispensing means is situated in a position in relation to said porous portion to provide for the delivery of said drug through said porous portion to body tissue.

19. A lead according to claims 17 or 18 wherein said drug is an anti-inflammatory agent.

15 20. A lead according to claim 19 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

21. A lead according to claim 19 wherein said drug is
20 the sodium salt of dexamethasone phosphate.

22. A lead according to claims 17 or 18 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

25 23. A lead according to claims 17 or 18 wherein said macroscopic surface area of said electrode is in the range of between 0.10 and 4.0 mm².

-31-

24. A lead according to claims 17 or 18 wherein said macroscopic surface area of said electrode is in the range of between 0.6 and 3.0 mm².

25. A lead according to claims 17 or 18 wherein the exposed surface of said electrode means is generally hemispheric to spherical in shape.

26. A lead according to claim 25 wherein said drug is an anti-inflammatory agent.

27. A lead according to claim 25 wherein said drug is the sodium salt of dexamethasone phosphate.

28. A lead according to claim 25 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

29. A lead according to claim 25 wherein said macroscopic surface area of said electrode is in the range of between 0.10 and 4.0 mm².

30. A lead according to claims 17 or 18 wherein said electrode means is formed of porous metallic or other conductive materials from the class of materials consisting essentially of platinum, palladium, titanium, tantalum, rhodium, iridium, carbon, vitreous carbon and alloys, oxides and nitrides of such metals or other conductive materials.

31. A lead according to claim 30 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

-32-

32. A lead according to claim 30 wherein said macroscopic surface area of said electrode is in the range of between 0.10 and 4.0 mm².

33. A lead according to claim 30 wherein said exposed macroscopic surface area of said electrode is in the range of between 0.60 and 3.0 mm².

34. A differential current density body stimulation and sensing lead comprising:
an electrical conductor having a proximal end and
10 a distal end;
electrical connector means coupled to the proximal end of said conductor;
electrode means coupled to said distal end of said conductor;
15 insulating sheath means for covering and electrically insulating said electrical conductor from body fluids and tissue extending between said electrode means and said connector means;
insulating body means coupled to said insulating
20 sheath and formed about said electrode means having an aperture therein for allowing fluid ingress to said electrode means, wherein said aperture is in the range of 0.1 to 4.0 mm² in area; and
drug dispensing means for dispensing a drug
25 within said chamber for allowing the elution of said drug through said aperture when wetted by the ingress of body fluids.

35. A lead according to claim 34 wherein said drug is an anti-inflammatory agent.

-33-

36. A lead according to claims 34 or 35 wherein said drug is the sodium salt of dexamethasone phosphate.

37. A lead according to claims 34 or 35 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating body means and adjacent said electrode means containing a water soluble form of said drug.

38. A lead according to claim 34 wherein said electrode means is formed of a length of electrically conductive wire coupled at one end to said distal end of said electrical conductor means.

39. A lead according to claim 38 wherein the exposed surface of said conductive wire is provided with a coating of metallic black.

40. A lead according to claim 39 wherein said exposed surface of said conductive wire is formed of porous platinum.

41. A lead according to claim 38 wherein said drug is an anti-inflammatory agent.

42. A lead according to claim 41 wherein said drug is the sodium salt of dexamethasone phosphate.

43. A lead according to claims 41 or 42 wherein said drug dispensing means comprises a water permeable polymer body located within said insulating body means and adjacent said electrode means containing a water soluble form of said drug.

-34-

44. A lead according to claim 34 wherein said electrode means is formed of porous metallic or other conductive materials from the class of materials consisting essentially of platinum, palladium, titanium, tantalum, 5 rhodium, iridium, carbon, vitreous carbon and alloys, oxides and nitrides of such metals or other conductive materials.

45. A lead according to claim 44 wherein said drug is an anti-inflammatory agent.

46. A lead according to claim 45 wherein said drug 10 dispensing means comprises a water permeable polymer body located within said insulating sheath lead and adjacent said electrode containing a water soluble form of said drug.

47. A lead according to claims 45 or 46 wherein said drug is the sodium salt of dexamethasone phosphate.

15 48. A lead according to claim 34 wherein said aperture is about 0.6 mm^2 in area.

49. A lead according to claims 34, 38, 44, or 48 wherein said exposed surface area of said electrode means within said insulating body means is about 50 mm^2 .

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04122

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A61N 1/05		
U.S. CL.: 128/784		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	128/784, 785, 786, 642	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X Y	US,A, 4,506,680 (STOKES) 26 MARCH 1985 see entire document	1,17,34 2-16,18-33 35-49
A	US,A, 4,502,492 (BORNZIN) 05 MARCH 1985 see entire document	1-49
A P	US,A, 4,953,564 (BERTHELSEN) 04 SEPTEMBER 1990 see entire document	1-49
A	US,A, 4,934,381 (MacGREGOR) 19 JUNE 1990 see abstract	1-49
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search.		Date of Mailing of this International Search Report
16 OCTOBER 1991		07 NOV 1991
International Searching Authority ISA/US		Signature of Authorized Officer SCOTT GETZOW <i>Scott Getzow</i>